Skip to content

Author

C. Lawrence

We have 2 of 83 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Repurposing the phospholipase A2 inhibitor, darapladib, to combat multidrug-resistant fungal pathogens, including Candida auris

Candida auris is an emerging multidrug-resistant fungal pathogen and a major global health threat, highlighting the urgent need for new therapeutics. We screened ~2,600 FDA-approved drugs and clinical compounds and identified darapladib (DAL), a phospholipase A2 inhibitor, as a potent antifungal agent against multidrug...

Yehia Elgammal, Ehab A. Salama, Nour M. Alkashef et al. · 0 citations
Open access Sep 2026

Structure-Activity Relationship Profiling of Substituted N-Phthalimidopiperidine Analogs as Broad-Spectrum Antifungal Agents.

SSD2032594 showed a survival benefit in the Caenorhabditis elegans nematode model of C. auris infection, resulting in a ∼30% higher survival rate, and is highlighted as a candidate for antifungal drug development, targeting infections caused by different fungal pathogens.

Matthew P. Dupuis, Nour M. Alkashef, Roman A. Matamoros et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.